๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
NCT03932331Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
AstraZeneca
Phase 1/2
105
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Haikou, Hangzhou
2020-04-29
Active, closed
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
NCT03934567Lymphoma, Follicular
Xynomic Pharmaceuticals, Inc.
Phase 2
87
Beijing, Changchun, Chengdu, Dalian, Fuzhou, Guangzhou, Hainan, Hangzhou
2020-04-22
Active, closed
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
NCT04603287Locally Advanced or Metastatic Epithelial Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Guangzhou, Chengdu, Hangzhou
2020-04-17
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
NCT04280081Solid Tumor, Medullary Thyroid Cancer
Eli Lilly and Company
Phase 2
77
Beijing, Guangzhou, Changsha, Changchun, Jinan, Shanghai, Tianjin, Hangzhou
2020-03-16
Recruiting
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542Prostate Cancer
Amgen
Phase 1
479
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou, Nanjing, Wenzhou
2020-03-04
Recruiting
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
NCT03907826Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2020-03-01
Recruiting
Microbial Colonization Distribution and Adaptive Evolution of Lower Respiratory Tract in Bronchiectasis Patients.
NCT04966793Bronchiectasis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,850
Hangzhou
2020-02-20
Active, closed
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499Breast Cancer
Hoffmann-La Roche
Phase 2/3
325
Beijing, Changchun, Chongqing, Fujian, Guangzhou, Hangzhou, Harbin, Shanghai
2020-01-29
Active, closed
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
NCT04075292Untreated Chronic Lymphocytic Leukemia
AstraZeneca
Phase 3
155
Beijing, Changchun, Changsha, Changzhou, Guangzhou, Guiyang, Hangzhou, Hefei
2020-01-20
Recruiting
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03936153Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.
Phase 2
170
Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou
2020-01-20
Active, closed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 3
354
Beijing, Zhengzhou, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Shanghai
2020-01-10
Recruiting
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
NCT04227015Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
He Huang
Phase EARLY_PHASE1
72
Hangzhou
2020-01-08
Active, closed
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
NCT04024696Non Hodgkin Lymphoma
Xynomic Pharmaceuticals, Inc.
Phase 1/2
12
Beijing, Hangzhou, Tianjin, Xuzhou
2020-01-08
Recruiting
Full 3D Eye Modeling in the Diagnosis and Treatment of Lens Diseases With Eye Structures Disorders
NCT07321769Lens Diseases
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,200
Hangzhou
2020-01-01
Recruiting
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
NCT06195228Advanced Thyroid Cancer Patients Who Received Target Therapy
Fudan University
Phase 4
800
Fuzhou, Zhengzhou, Wuhan, Hohhot, Shanghai, Shanxi, Hangzhou, Beijing
2020-01-01
Active, closed
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
NCT04208347Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital
Phase 2/3
580
Baoding, Beijing, Changsha, Changzhi, Chengdu, Guiyang, Haikou, Hangzhou
2019-12-18
Active, closed
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 3
461
Beijing, Fuzhou, Hubei Sheng, Changsha, Shanghai, Chengdu, Hangzhou
2019-11-05
Recruiting
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
NCT03983226Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 2
167
Shanghai, Guangzhou, Hangzhou
2019-10-18
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Tianjin, Xi'an, Hangzhou
2019-10-03
Recruiting
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma โ‰ค 2cm
NCT04937283Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
690
Hefei, Nanyang, Nantong, Xuzhou, Yancheng, Jinan, Shanghai, Hangzhou
2019-10-01
Active, closed
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04076059Metastatic Hormone Sensitive Prostate Cancer
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Nanchang, Shanghai
2019-09-11
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1
701
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2019-09-04
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Active, closed
Westlake Precision Birth Cohort
NCT04060056Diabetes, Gestational, Pregnancy in Diabetics, Intrauterine Hyperglycemia
Westlake University
Not applicable
2,001
Hangzhou
2019-08-30
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
Beijing, Changchun, Chengdu, Guangzhou, Haikou, Hangzhou, Lanzhou, Nanjing
2019-08-15
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Celgene
Phase 3
665
Beijing, Guangzhou, Shanghai, Chengdu, Tianjin, Hangzhou
2019-08-12
Active, closed
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
NCT03791112Advanced Solid Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 1
54
Hangzhou
2019-07-18
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
587
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2019-07-02
Recruiting
Transpacific TAVR Registry
NCT03826264Heart Valve Diseases, Aortic Valve Insufficiency
Duk-Woo Park, MD
Observational
10,000
Hangzhou
2019-06-15
Active, closed
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
NCT03913949Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Ascentage Pharma Group Inc.
Phase 1
74
Hefei, Zhengzhou, Wuhan, Tianjin, Hangzhou
2019-06-03
Active, closed
Effisayilโ„ข ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
NCT03886246Generalized Pustular Psoriasis
LEO Pharma
Phase 2
131
Guangzhou, Hangzhou, Shanghai, Xi'an
2019-05-29
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
AstraZeneca
Phase 3
908
Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2019-04-29
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
AstraZeneca
Phase 3
810
Baoding, Beijing, Bengbu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin
2019-04-16
Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407Hyperkalaemia
AstraZeneca
Phase 3
140
Beijing, Changsha, Chengdu, Chongqing, Hangzhou, Hefei, Shanghai
2019-04-02
Recruiting
Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
NCT03713879Post ERCP Pancreatitis
Chinese University of Hong Kong
Phase 3
1,734
Xi'an, Shanghai, Tianjin, Hangzhou
2019-03-21
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Hefei, Jinan
2019-03-06
Recruiting
Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
NCT03703271Gestational Trophoblastic Neoplasia
Women's Hospital School Of Medicine Zhejiang University
Phase 3
70
Hangzhou
2019-03-01
Active, closed
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
984
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang
2019-02-25
Active, closed
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
NCT03754790Hemophilia
Genzyme, a Sanofi Company
Phase 3
281
Beijing, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2019-01-09
Recruiting
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC๏ผ‰
NCT03941561Gastric Cancer
Fudan University
Phase 3
1,006
Anqing, Hangzhou, Hefei, Nanchang, Shanghai, Wuhu
2019-01-01
Recruiting
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
NCT03785574Hydatidiform Mole, Gestational Trophoblastic Neoplasia
Women's Hospital School Of Medicine Zhejiang University
Not applicable
30
Hangzhou
2018-12-24
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
507
Fuzhou, Haikou, Zhengzhou, Changsha, Hengyang, Suzhou, Wuxi, Hangzhou
2018-11-28
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Takeda
Phase 3
245
Zhengzhou, Suzhou, Changchun, Hangzhou, Tianjin
2018-10-04
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
AstraZeneca
Phase 3
1,246
Beijing, Changchun, Changsha, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan
2018-09-27
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
AstraZeneca
Phase 3
730
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2018-09-27
Active, closed
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Phase 3
257
Beijing, Changchun, Chengdu, Fujian, Guangzhou, Hangzhou, Jinan, Shanghai
2018-08-16
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
AbbVie
Phase 3
1,533
Beijing, Guangzhou, Wuhan, Shenyang, Hangzhou, Changsha, Shanghai
2018-08-09
Active, closed
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
NCT03521154Non Small Cell Lung Cancer (Stage III)
AstraZeneca
Phase 3
216
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Linhai
2018-07-19
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
Eli Lilly and Company
Phase 3
1,058
Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2018-07-18
Recruiting
Peri-operative Nutrition in Infants With Congenital Heart Disease
NCT03626480Congenital Heart Disease
Guangzhou Medical University
Observational
20,000
Hangzhou
2018-07-09
Active, closed
Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients
NCT03777969Chronic Hepatitis b
Beijing Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Wuxi, Shanghai, Hangzhou
2018-06-29
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
565
Haerbin, Nanjing, Hangzhou, Beijing, Hefei, Xiamen, Zhengzhou
2018-06-21
Recruiting
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
NCT04283006Relapsed and Refractory, Lymphoid Hematological Malignancies
He Huang
Phase EARLY_PHASE1
100
Hangzhou
2018-05-23
Active, closed
International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer
NCT03386734Cervical Cancer
Centre Hospitalier Universitaire de Besancon
Not applicable
989
Hangzhou, Wenzhou
2018-05-03
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Tianjin, Beijing, Guangzhou, Changsha, Shanghai, Xiโ€™an, Hangzhou, Ningbo
2018-04-24
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
Janssen Research & Development, LLC
Phase 2/3
1,409
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2018-04-13
Recruiting
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
NCT03498326Pancreatic Cancer, Chemotherapy Effect
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
480
Hangzhou
2018-04-02
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
Janssen Research & Development, LLC
Phase 3
629
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing
2018-03-23
Recruiting
VitaFlowโ„ข II Transcatheter Aortic Valve System Pre-market Trial
NCT04414878Aortic Stenosis
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Not applicable
145
Beijing, Shanghai, Chengdu, Hangzhou
2018-01-31
Active, closed
Prognostic Impact of Coronary Microvascular Dysfunction After IVL Versus RA in Patients With Severe Coronary Calcification Undergoing PCI
NCT07699965Coronary Artery Calcification, Intravascular Lithotripsy, Coronary Microcirculation Dysfunction
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
590
Hangzhou
2018-01-01
Active, closed
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT03319667Plasma Cell Myeloma
Sanofi
Phase 3
475
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang
2017-12-07
Active, closed
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
NCT03182244AML With FLT3 Mutation
Astellas Pharma Inc
Phase 3
276
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei
2017-10-25
Active, closed
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,324
Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou
2017-10-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
Institut de Recherches Internationales Servier
Phase 3
146
Zhengzhou, Chengdu, Beijing, Guangzhou, Hangzhou, Tianjin
2017-06-26
Recruiting
China Headache and Vertigo Registry Study
NCT04939922Headache Disorders, Primary, Headache Disorders, Secondary, Migraine, Tension-Type Headache
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou
2017-06-12
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
AstraZeneca
Phase 3
1,186
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2017-06-01
Active, closed
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608Carcinoma, Non-Small-Cell Lung
Pfizer
Phase 3
296
Beijing, Changchun, Shanghai, Hangzhou, Guangzhou
2017-04-27
Active, closed
Durvalumab ยฑ Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
NCT03043872Small Cell Lung Carcinoma Extensive Disease
AstraZeneca
Phase 3
987
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Hangzhou, Hefei
2017-03-27
Recruiting
Valvular Heart Disease Registry Study in Second Affiliated Hospital of ZheJiang University
NCT03011697Valvular Heart Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou
2017-02-01
Recruiting
Clinical Outcomes Following Primary Intracerebral Hemorrhage
NCT06548737Stroke, Intracerebral Hemorrhage
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
25,000
Hangzhou
2016-10-27
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2016-09-13
Active, closed
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
NCT02859038Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 3
489
Guangzhou, Shanghai, Hangzhou, Changsha
2016-08
Active, closed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116Carcinoma, Non-Small-Cell Lung
Takeda
Phase 1/2
334
Beijing, Wuhan, Shanghai, Hangzhou
2016-06-16
Active, closed
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
NCT02609776Non-Small-Cell Lung Cancer
Janssen Research & Development, LLC
Phase 1
751
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei
2016-05-24
Recruiting
Computer-based Online Database of Acute Stroke Patients for Stroke Management Quality Evaluation
NCT04487340Stroke, Acute
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
200,000
Hangzhou
2016-01-01
Active, closed
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai
2015-11-27
Active, closed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
Hoffmann-La Roche
Phase 2
534
Harbin, Wuhan, Chengdu, Beijing, Guangzhou, Hangzhou, Shanghai, Shenzhen
2015-11-19
Active, closed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516Prostatic Neoplasms
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2015-11-19
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
AstraZeneca
Phase 3
953
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Shanghai, รœrรผmqi, Wuhan
2015-11-03
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
AstraZeneca
Phase 3
1,126
Beijing, Changchun, Changsha, Chongqing, Hangzhou, Nanjing, Shanghai, Shenyang
2015-11-02
Active, closed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
1,280
Beijing, Guangzhou, Hangzhou, Hefei, Shanghai, Shengyang, Shenyang, Suzhou
2015-10-31
Active, closed
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma
AstraZeneca
Phase 3
682
Beijing, Changchun, Dalian, Guangzhou, Hangzhou, Kunming, Nanjing, Nanning
2015-10-21
Active, closed
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
NCT02519348Hepatocellular Carcinoma
MedImmune LLC
Phase 2
433
Hangzhou, Nanjing, Shanghai
2015-10-19
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
Novartis Pharmaceuticals
Phase 4
279
Hangzhou, Beijing
2015-03-05
Active, closed
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
NCT02320435Solid Tumors
Hoffmann-La Roche
Phase 3
154
Beijing, Changchun, Chengdu, Hangzhou, Harbin, Nanjing, Shanghai, Shenyang
2015-02-02
Active, closed
Prognostic Values of Coronary Microvascular Dysfunction Patients Treated with Rotational Atherectomy During Percutaneous Coronary Intervention
NCT06702748Coronary Arterial Disease (CAD), Coronary Microvascular Dysfunction (CMD)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
452
Hangzhou
2015-01-01
Recruiting
A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation
NCT06076226Acute Leukemia
Zhejiang University
Observational
2,500
Hangzhou
2015-01-01
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631Non Small Cell Lung Cancer
Eli Lilly and Company
Phase 3
453
Beijing, Changchun, Changzhou, Chengdu, Haikou, Hangzhou, Hefei, Nanning
2014-10-03
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
AstraZeneca
Phase 3
1,837
Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing
2014-04-22
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
700
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shanxi, Suzhou
2013-09-09
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
AstraZeneca
Phase 3
327
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
AstraZeneca
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2013-08-26
Recruiting
the National Colorectal Cancer Cohort (NCRCC) Study: National Colorectal Cancer Research Consortium
NCT04074538Colorectal Cancer
Ding Ke-Feng
Observational
55,000
Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai
2013-01-01
Active, closed
The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma
NCT01820884Endometrial Neoplasms
Ding Ma
Not applicable
240
Wuhan, Jinan, Hangzhou
2012-11
Active, closed
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
NCT01820858Endometrial Neoplasms
Ding Ma
Phase 3
300
Wuhan, Jinan, Hangzhou
2012-11
Rows per page Showing 1701–1800 of 1812
Previous 16 17 18 19 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=18

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.